Lymphoma
Conditions
Brief summary
Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis lymphoma
Interventions
None listed
Sponsors
Armando Santoro, MD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line that * Signed informed consent to perform an haploidentical allo-BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of T lymphocytes and NK cells absolute number | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of discrete T-cells populations | 1 year | Evaluation, by flow cytometry, of discrete T cell populations, including CD4+ and CD8+ TN, TSCM, TCM and TEM, NK and NKT cells, B cells, dendritic cell subsets |
| Evaluation of antigen-specific T cell populations | 1 year | Evaluation of antigen-specific T cell frequency towards CMV, EBV and influenza virus by MHC tetramers |
| Evaluation of antigen-specific T lymphocyte's functionality | 1 year | antigen-specific T lymphocyte's functionality towards tumor cell line evaluated using a degranulation assay |
| Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells | 1 year | — |
Countries
Italy
Outcome results
None listed